Bispecific Antibodies
•60 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (60)
| Company | Market Cap | Price |
|---|---|---|
|
JNJ
Johnson & Johnson
The company markets bispecific antibodies (TECVAYLI, TALVEY), a distinct antibody modality.
|
$509.56B |
$214.04
+1.16%
|
|
ABBV
AbbVie Inc.
AbbVie is pursuing bispecific antibodies (e.g., ABBV-383), a distinct oncology modality.
|
$394.51B |
$226.96
+1.63%
|
|
AZN
AstraZeneca PLC
IO bispecific antibodies are a key immuno-oncology modality in AZN's pipeline.
|
$278.47B |
$91.06
+1.37%
|
|
MRK
Merck & Co., Inc.
The pipeline includes bispecific antibodies/T-cell engagers developed via acquisitions/collaborations.
|
$250.53B |
$99.66
-0.64%
|
|
AMGN
Amgen Inc.
Amgen leverages a bispecific antibody platform (BiTEs) in its oncology programs (e.g., BLINCYTO) and related assets.
|
$171.06B |
$319.44
+0.54%
|
|
BMY
Bristol-Myers Squibb Company
BioNTech collaboration on BNT327 represents Bispecific Antibodies as a direct modality.
|
$106.68B |
$54.11
+3.24%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
The company is advancing bispecific antibodies (e.g., Lynozyfic, Odronextamab) as a key modality.
|
$78.57B |
$751.00
+1.31%
|
|
BNTX
BioNTech SE
BNT327 is a bispecific antibody (PD-L1 x VEGF-A), a direct Bispecific Antibodies product category.
|
$22.73B |
$93.71
-1.16%
|
|
GMAB
Genmab A/S
Genmab's DuoBody bispecific antibody technology powers its bispecific therapies, aligning with Bispecific Antibodies.
|
$20.72B |
$31.49
+0.57%
|
|
INCY
Incyte Corporation
TGFßR2xPD-1 bispecific represents a distinct antibody modality in development, a separate investable category.
|
$18.63B |
$96.33
+0.96%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is a PD-1/VEGF bispecific antibody, placing Summit in the Bispecific Antibodies investable theme.
|
$13.05B |
$17.27
-1.71%
|
|
EXEL
Exelixis, Inc.
XB628 is a bispecific antibody developed by Exelixis.
|
$11.00B |
$41.27
+0.94%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.16B |
$169.33
+1.09%
|
|
MRUS
Merus N.V.
Technology platforms enable bispecific antibodies (and multispecifics), a primary Merus offering.
|
$7.33B |
$96.77
-0.17%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody aims to create conditionally-active antibodies engaging CD3, consistent with 'Bispecific Antibodies'.
|
$3.55B |
$26.13
-1.43%
|
|
IDYA
IDEAYA Biosciences, Inc.
Pipeline includes a bispecific antibody modality (e.g., IDE034) targeting two cancer-related antigens.
|
$2.98B |
$33.72
-0.88%
|
|
ZLAB
Zai Lab Limited
Bispecific antibody programs (e.g., dual-target antibodies) advancing in oncology/immunology.
|
$1.95B |
$17.52
-1.44%
|
|
ZYME
Zymeworks Inc.
Zymeworks' portfolio includes bispecific antibodies and multispecific antibody therapeutics (MSATs).
|
$1.92B |
$25.58
+0.39%
|
|
IMCR
Immunocore Holdings plc
ImmTACs are bispecific TCR constructs; platform enables bispecific modalities.
|
$1.85B |
$35.83
-2.64%
|
|
CLDX
Celldex Therapeutics, Inc.
CDX-622 is a bispecific antibody in Celldex's pipeline, aligning with Bispecific Antibodies as a core modality.
|
$1.83B |
$27.00
-1.85%
|
|
ZBIO
Zenas BioPharma, Inc.
Lead asset obexelimab is a bispecific antibody engaging two targets.
|
$1.71B |
$34.87
-14.09%
|
|
KOD
Kodiak Sciences Inc.
KSI-501 and KSI-101 are bispecific proteins, aligning with Bispecific Antibodies.
|
$1.26B |
$22.79
-4.28%
|
|
XNCR
Xencor, Inc.
Company develops and advances bispecific antibodies (XmAb 2+1 formats) for oncology and autoimmune indications.
|
$1.18B |
$16.57
+0.33%
|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$1.10B |
$1.37
-0.72%
|
|
ABCL
AbCellera Biologics Inc.
T-cell engager / bispecific antibody programs are part of AbCellera's pipeline.
|
$1.08B |
$3.48
-3.73%
|
|
NKTR
Nektar Therapeutics
NKTR-0166 is a bispecific antibody program, fitting Bispecific Antibodies as an investable theme.
|
$1.04B |
$52.56
-3.91%
|
|
IMTX
Immatics N.V.
TCR Bispecifics platform (bispecific antibodies engaging tumor cells and T cells).
|
$1.04B |
$9.94
-1.00%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead candidate ficerafusp alfa is a bispecific antibody targeting two pathways, fitting Bispecific Antibodies.
|
$1.01B |
$18.14
-1.84%
|
|
MLTX
MoonLake Immunotherapeutics
SLK is a multispecific antibody/ Nanobody targeting IL-17A/F, aligning with the Bispecific Antibodies investable theme.
|
$949.97M |
$14.43
-2.43%
|
|
VIR
Vir Biotechnology, Inc.
Dual-masked bispecific antibodies (T-cell engagers) constitute a primary oncology platform.
|
$929.35M |
$6.71
+0.22%
|
|
JANX
Janux Therapeutics, Inc.
Core product modality is Bispecific Antibodies engineered to engage T cells in a tumor-activated manner.
|
$919.44M |
$14.98
-2.06%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$704.17M |
$11.29
-5.29%
|
|
CTMX
CytomX Therapeutics, Inc.
The PROBODY platform extends to masked T-cell engagers, aligning with Bispecific Antibodies as a modality.
|
$690.99M |
$4.11
-1.91%
|
|
IMAB
I-Mab
I-Mab's portfolio includes bispecific antibodies (e.g., givastomig and ragistomig), a core modality for multi-target engagement.
|
$533.68M |
$4.64
|
|
ACRS
Aclaris Therapeutics, Inc.
ATI-52.00 is a bispecific antibody, fitting the Bispecific Antibodies category.
|
$352.08M |
$3.22
-0.92%
|
|
OABI
OmniAb, Inc.
OmniAb's platforms enable discovery of Bispecific Antibodies (OmniFlic/OmniClic), a major therapeutic modality.
|
$263.81M |
$2.10
-2.56%
|
|
ZURA
Zura Bio Limited
Tibulizumab is a bispecific antibody targeting IL-17A and BAFF (Bispecific Antibodies).
|
$261.37M |
$4.01
-0.25%
|
|
CBIO
Crescent Biopharma, Inc.
CR-001 is a bispecific antibody (PD-1 x VEGF), fitting the Bispecific Antibodies investable theme.
|
$195.75M |
$13.72
-2.63%
|
|
IPHA
Innate Pharma S.A.
ANKET NK cell engagers (e.g., IPH6501) are bispecific antibody-based constructs engaging NK cells with tumor targets.
|
$150.60M |
$1.84
-0.81%
|
|
STTK
Shattuck Labs, Inc.
Pipeline includes DR3 bispecific antibodies, reflecting a major bsAb product modality.
|
$148.50M |
$2.94
-5.00%
|
|
MOLN
Molecular Partners AG
Multi-target engaging modality (Switch-DARPin) aligns with bispecific antibody/category dynamics.
|
$143.56M |
$4.15
-4.05%
|
|
CGEN
Compugen Ltd.
Rilvegostomig is a PD-1/TIGIT bispecific antibody; CGEN contributes the TIGIT component, aligning with Bispecific Antibodies.
|
$136.99M |
$1.50
-2.29%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$93.29M |
$1.05
+1.44%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$88.49M |
$1.38
-1.43%
|
|
ADAG
Adagene Inc.
Bispecific antibodies (e.g., ADG138 HER2xCD3 POWERbody) in the pipeline.
|
$77.47M |
$1.68
-4.00%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's CD20 x CD3 bispecific candidate demonstrates a bispecific antibody modality.
|
$76.35M |
$1.27
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$73.18M |
$10.79
-0.42%
|
|
CMPX
Compass Therapeutics, Inc.
Core asset strategy centers on Bispecific Antibodies (e.g., DLL4 x VEGF-A; PD-1 x PD-L1; PD-1 x VEGF-A).
|
$65.15M |
$5.13
-0.48%
|
|
ANL
Adlai Nortye Ltd.
ANL’s AN8025 is a multi-specific antibody fusion protein, aligning with the Bispecific Antibodies category.
|
$50.87M |
$1.43
+3.62%
|
|
HOWL
Werewolf Therapeutics, Inc.
WTX-1011 is a T-cell engager (bispecific) targeting STEAP1, mapping to Bispecific Antibodies.
|
$50.30M |
$1.09
-0.45%
|
|
BCAB
BioAtla, Inc.
BA3182 is a bispecific EpCAM x CD3 T-cell engager, a bispecific antibody.
|
$48.41M |
$0.79
-3.61%
|
|
LVTX
LAVA Therapeutics N.V.
Gammabody antibodies are bispecific antibodies designed to engage gamma delta T cells for anti-tumor activity.
|
$45.76M |
$1.65
-5.17%
|
|
IBIO
iBio, Inc.
Pipeline includes Bispecific Antibodies such as TROP-2 x CD3 and MUC16 x CD3, reflecting a Bispecific Antibodies focus.
|
$38.13M |
$1.94
-0.26%
|
|
XLO
Xilio Therapeutics, Inc.
Xilio's masked T cell engager programs (ATACR/SEECR) correspond to Bispecific Antibodies.
|
$37.95M |
$0.73
+0.33%
|
|
AKTX
Akari Therapeutics, Plc
Lead to Bispecific ADC (AKTX-102) using PH1 payload, aligning with Bispecific Antibodies.
|
$19.28M |
$0.39
+0.08%
|
|
THAR
Tharimmune, Inc.
THAR's pipeline includes bispecific antibodies (HS1940, HS3215), aligning with Bispecific Antibodies.
|
$11.08M |
$2.38
-0.21%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Genmab collaboration targets next-generation bispecific ISACs, indicating a Bispecific Antibodies program.
|
$10.44M |
$5.51
+1.29%
|
|
INAB
IN8bio, Inc.
The INB-600 gamma-delta T cell engager platform suggests bispecific antibody-like T cell engagers.
|
$7.63M |
$1.64
-2.68%
|
|
HCWB
HCW Biologics Inc.
TRBC-derived immune cell engagers and multi-specific targeting align with Bispecific Antibodies as a modality.
|
$3.89M |
$1.79
-1.10%
|
|
APVO
Aptevo Therapeutics Inc.
APVO's lead therapies are bispecific antibodies (and trispecifics) designed to engage T cells and tumor targets using its ADAPTIR/ADAPTIR-FLEX platforms.
|
$3.72M |
$1.07
-5.31%
|
Loading company comparison...
Loading industry trends...
Loading research report...
